. . . .Vertex Pharmaceuticals today closed upon the agreement to sell 11,500,000 shares of the common stock in a firmly-committed underwritten charity during a price to a public of $38.50 per share, which resulted in total gross proceeds of $442.8 million. . . . Goldman, Sachs & Co. acted as a sole book-running manager for a offering, in an charity underneath which BofA Merrill Lynch, J.P. Morgan Securities Inc., as well as Morgan Stanley & Co. Incorporated acted as co-managers. . . .
Regular readers will stop that Vertex is leading New Merck (as successor to Schering-Plough's investigate in this area) in a race for next-gen Hep C treatments. This nearby half billion will give (the rather small) Vertex one more coherence to accelerate the outlay upon the Phase III efforts, as well as expected correspondingly digest the time to approval during FDA.
No comments:
Post a Comment